LEADER 03171nam  2200457z- 450 
001 9910261134503321
005 20210211
035   $a(CKB)4100000002484747
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/50155
035   $a(oapen)doab50155
035   $a(EXLCZ)994100000002484747
100   $a20202102d2017      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aInduction of Central Nervous System Disease by the Adaptive Immune Response
210   $cFrontiers Media SA$d2017
215   $a1 online resource (141 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88945-347-2 
330   $aOver the last years it has become evident that many neurological diseases of the central nervous system (CNS) are induced by a specific adaptive immune response directed against molecules expressed on CNS-resident cells. Well-recognized examples are anti-N-Methyl-D-Aspartate Receptor (NMDAR) encephalitis which is characterized by the presence of antibodies against neuron-expressed NMDAR, or neuromyelitis optica (NMO), induced by antibodies to astrocyte-expressed aquaporin-4. Many more examples exist, and antibodies, and T or/and B cells have increasingly been associated with CNS disease. Often the symptoms of these diseases have not been typically reported to have an immune aetiology. Beside classical neurological symptoms like ataxia, vision disturbance, and motor or sensory symptoms, these can include cognitive disturbances, behavioral abnormalities, or/and epileptic seizures. Although much has been learned regarding the pathophysiology of prototypic examples of these disorders, there are still major gaps in our understanding of their biology. This may be due to the fact that they are rare diseases, and their therapies are still very limited. This research topic includes contributions addressing the analysis of the adaptive immune response driving disease including target antigens, molecular epitope mapping, and factors involved in the disease pathogenesis such as complement activation cascades, genetic and genomic regulation, as well as environmental triggers. Diagnostic criteria and methods, and treatment are also discussed. The overall aim of the volume is to review progress in our pathophysiological understanding of immune-mediated CNS disorders in order to advance diagnostic and therapeutic approaches, and ultimately improve outcomes for patients.
606   $aMedicine$2bicssc
610   $aaquaporin-4
610   $aautoimmune encephalitis
610   $aautophagy
610   $aB cells
610   $amultiple sclerosis
610   $amyelin oligodendrocyte glycoprotein
610   $aneuromyelitis optica spectrum disorder
610   $aNMDA receptor
610   $aT cell
610   $athyroid gland
615  7$aMedicine
700   $aFabienne Brilot$4auth$01311260
702   $aRobert Weissert$4auth
906   $aBOOK
912   $a9910261134503321
996   $aInduction of Central Nervous System Disease by the Adaptive Immune Response$93030067
997   $aUNINA